talabostat
Small moleculeexperimental
Clinical trial activity
14 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
11
Phase 3
2
Phase 4
0
Earliest trial started Mar 23, 2004 (NCT00080080)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Brain Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Small Cell · Phase 1/Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 3
- Melanoma · Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 1
- Neuroendocrine Tumors · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1
- Skin Neoplasms · Phase 2
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O- Mol. weight
- 214.07 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL67279 ↗
- ChEMBLCHEMBL3545064 ↗
Also known as
- l-valinyl-l-boroproline
- pt 100
- pt-100
- pt-100
- pt-100
- pt100 cpd
- talabostat
- talabostat
- talabostat
- talabostat
- talabostat mesylate
- talabostat mesylate
- valinyl-boroproline
- valinyl-l-boroproline
- valinyl-l-boroproline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05703542 | Phase 1 | Feb 2, 2023 | Harvard University |
| NCT05558982 | Phase 2 | Dec 31, 2022 | BioXcel Therapeutics Inc, Georgetown University |
| NCT04171219 | Phase 2 | Apr 30, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04123574 | Early Phase 1 (Phase 1) | Oct 15, 2019 | BioXcel Therapeutics Inc, IQVIA |
| NCT03910660 | Phase 1/Phase 2 (Phase 2) | Feb 12, 2019 | BioXcel Therapeutics Inc |
| NCT00489710 | Phase 2 | Dec 1, 2006 | National Cancer Institute (NCI), University of Nebraska |
| NCT00290017 | Phase 3 | Feb 1, 2006 | Point Therapeutics |
| NCT00243204 | Phase 3 | Jan 1, 2006 | Point Therapeutics |
| NCT00303940 | Phase 1 | Dec 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00116389 | Phase 2 | Jun 28, 2005 | Point Therapeutics |
| NCT00086203 | Phase 2 | Jun 28, 2004 | Point Therapeutics |
| NCT00083252 | Phase 2 | May 14, 2004 | Point Therapeutics |
| NCT00083239 | Phase 2 | May 14, 2004 | Point Therapeutics |
| NCT00080080 | Phase 2 | Mar 23, 2004 | Point Therapeutics |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Point Therapeutics | For profit | 7 | 7 | 2 | 2004 |
| BioXcel Therapeutics Inc | For profit | 3 | 2 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2005 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| IQVIA | For profit | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2005 |
| University of Nebraska | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2020 |
9 organizations
Page 1 / 1